Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings

For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $127.17 million, representing a surprise of +11.66%. The company delivered an EPS surprise of +28.76%, with the consensus EPS estimate being -$2.99.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Product sales- United States: $88 million versus the three-analyst average estimate of $28.31 million. The reported number represents a year-over-year change of -45.7%.Product sales- Rest of world: $26 million compared to the $42.95 million average estimate based on two analysts. The reported number represents a change of +18.2% year over year.Revenue- Net Product sales: $114 million versus $81.42 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -38% change.Revenue- Other revenue: $28 million versus the six-analyst average estimate of $25.13 million. The reported number represents a year-over-year change of -50.9%.Revenue- Other revenue- Grant revenue: $5 million compared to the $6.16 million average estimate based on three analysts.Revenue- Other revenue- Licensing & royalty revenue: $2 million versus $10.65 million estimated by two analysts on average.Revenue- Other revenue- Collaboration revenue: $4 million versus the two-analyst average estimate of $7.5 million.View all Key Company Metrics for Moderna here>>>Shares of Moderna have returned -3.1% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks